SNN

Merger breakdown puts Smith & Nephew in the spotlight The collapse of Johnson & Johnson's proposed merger with Smith & Nephew (LSE:SN.) after a leadership dispute keeps control with CEO Deepak Nath and leaves investors reassessing the standalone medical…

Smith & Nephew has delivered a 39.1% gain over the past three years, yet the real question for anyone looking at the stock today is how well that share price lines up with the cash the business can generate.

Johnson & Johnson (JNJ:NYSE) shares closed down 1. 42% at $263.

Key Stats for Johnson & Johnson StockPrice change for Johnson & Johnson stock in last 6 months: 14%$JNJ Stock Price as of Oct.

(Corrects to clarify that Smith & Nephew declined to comment and updates the second paragraph with m

(Updates with Smith & Nephew's clarification in the second paragraph.) Johnson & Johnson's (JNJ)

SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.

Smith & Nephew's (SNN) CartiHeal Agili-C Cartilage Repair Implant is now commercially available in E

Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización en Europa.

Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l’innovativo impianto per la riparazione della cartilagine.

SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.